BUDGET IMPACT ANALYSIS OF ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM

被引：1
|
作者：
Vitale, V. [1 ]
Asano, E. [1 ]
Pereira, M. L. [1 ]
机构：
[1] Janssen Cilag Farmaceut, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.1908
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A665 / A665
页数：1
相关论文
共 50 条
  • [1] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
    Yang, Lily P. H.
    DRUGS, 2011, 71 (15) : 2067 - 2077
  • [2] The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
    Onal, Cem
    Sedef, Ali Murat
    Kose, Fatih
    Oymak, Ezgi
    Guler, Ozan Cem
    Sumbul, Ahmet Taner
    Aksoy, Sercan
    Yildirim, Berna Akkus
    Besen, Ali Ayberk
    Muallaoglu, Sadik
    Mertsoylu, Huseyin
    Ozyigit, Gokhan
    FUTURE ONCOLOGY, 2019, 15 (13) : 1469 - 1479
  • [3] Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
    Brasso, Klaus
    Thomsen, Frederik B.
    Schrader, Andres J.
    Schmid, Sebastian C.
    Lorente, David
    Retz, Margitta
    Merseburger, Axel S.
    von Klot, Christoph A.
    Boegemann, Martin
    de Bono, Johann
    EUROPEAN UROLOGY, 2015, 68 (02) : 317 - 324
  • [4] TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL IN PORTUGAL
    Silva Miguel, L.
    Paquete, A. T.
    Guerreiro, R.
    Fiorentino, F.
    Costa, J.
    Borges, M.
    VALUE IN HEALTH, 2018, 21 : S71 - S71
  • [5] ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    de Boer, Carla
    Todd, Mary
    Yu, Margaret K.
    Scher, Howard I.
    CANCER RESEARCH, 2014, 74 (19)
  • [6] NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
    Dyer, Matthew
    Rinaldi, Fiona
    Adler, Amanda I.
    LANCET ONCOLOGY, 2012, 13 (08): : 762 - 763
  • [7] Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
    Sternberg, C. N.
    Molina, A.
    North, S.
    Mainwaring, P.
    Fizazi, K.
    Hao, Y.
    Rothman, M.
    Gagnon, D. D.
    Kheoh, T.
    Haqq, C. M.
    Cleeland, C.
    de Bono, J. S.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 1017 - 1025
  • [8] Health care resource utilization and costs in metastatic castration-resistant prostate cancer patients treated with enzalutamide or abiraterone acetate.
    Kassabian, Vahan
    Flanders, Scott
    Wilson, Samuel
    Brown, Bruce A.
    Song, Yan
    Yang, Hongbo
    Lechpammer, Stanislav
    Schultz, Neil M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer
    Clayton, Ravinder
    Wu, Jackson
    Heng, Daniel Y.
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien
    Chi, Kim
    Zielinski, Rob
    Al-Shamsi, Humaid
    Chen, Leo
    Eigl, Bernhard
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (9-10): : E583 - E590
  • [10] The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
    Cem, Onal
    Sedef, Ali Murat
    Kose, Fatih
    Oymak, Ezgi
    Guler, Ozan Cem
    Sumbul, Ahmet Taner
    Aksoy, Sercan
    Yildrim, Berna Akkus
    Besen, Ali Ayberk
    Mullaoglu, Sadik
    Mertsoylu, Huseyin
    Ozyigit, Gokhan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345